Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
17 hedge funds and large institutions have $1.75M invested in Better Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
88% more call options, than puts
Call options by funds: $360K | Put options by funds: $191K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 16 → 17 (+1)
44% less capital invested
Capital invested by funds: $3.11M → $1.75M (-$1.37M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$29.9K |
| 2 |
BlackRock
New York
|
+$2.43K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$302 |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$199 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$27 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$275K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$19K |
| 4 |
Two Sigma Investments
New York
|
-$9.86K |
| 5 |
Millennium Management
New York
|
-$3.88K |
BTTX Hedge Fund Activity: Q4 2022 in Review
17 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q4 2022, worth a combined $1.75M — down 44% from $3.11M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BTTX positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Group One Trading, opening a new position worth an estimated $29.9K. The largest seller was Farallon Capital Management, cutting an estimated $275K.
- 17 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q4 2022, up from 16 in Q3 2022.
- Funds reported $1.75M of Better Therapeutics, Inc. Common Stock stock for Q4 2022, down 44% quarter-over-quarter.
- 3 funds opened new Better Therapeutics, Inc. Common Stock positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q4 2022 was Group One Trading, an estimated $29.9K added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q4 2022 was Farallon Capital Management, an estimated $275K sold.
Based on aggregated 13F filings for Q4 2022.